Case series finds no adverse reaction to tecovirimat in four pregnant persons with mpox

A surveillance case series from the United States described mpox cases among cisgender women, including pregnant persons. The report noted the use of tecovirimat treatment in this population but did not provide a comparator group, primary outcome, or total sample size. Regarding safety, the report stated that 0 of 4 pregnant persons treated with tecovirimat experienced an adverse reaction. Serious adverse events, discontinuations, and tolerability were not reported. Key limitations include the small number of treated cases, the absence of a control group, and lack of reported follow-up duration. The report's funding and conflicts of interest were not disclosed. Given the observational nature and limited data, these findings do not establish the safety or efficacy of tecovirimat in pregnancy but may inform ongoing surveillance efforts.